Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKG:9989)

HKG:9989 Revenue

Shenzhen Hepalink Pharmaceutical Group had revenue of 1.38B CNY in the quarter ending September 30, 2025, with 11.82% growth. This brings the company's revenue in the last twelve months to 5.38B, down -0.96% year-over-year. In the year 2024, Shenzhen Hepalink Pharmaceutical Group had annual revenue of 5.26B, down -3.17%.

• Revenue (ttm): 5.38B CNY
• Revenue Growth: -0.96%
• P/S Ratio: 3.02
• Revenue / Employee: 2.80M CNY
• Employees: 1,926
• Market Cap: 17.75B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	5.26B	-172.06M	-3.17%
Dec 31, 2023	5.43B	-1.73B	-24.14%
Jan 1, 2023	7.16B	794.23M	12.48%
Jan 1, 2022	6.37B	1.03B	19.38%
Dec 31, 2020	5.33B	707.42M	15.30%